Terms: = Prostate cancer AND CgA AND Treatment
82 results:
1. Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer.
Lewis AR; Costello BA; Quevedo F; Pagliaro LC; Sanhueza C; Weinshilboum RM; Kalari KR; Wang L; Kohli M; Tan W; Giridhar KV
Prostate; 2023 May; 83(7):649-655. PubMed ID: 36924119
[TBL] [Abstract] [Full Text] [Related]
2. Chromogranin A: a useful biomarker in castration-resistant prostate cancer.
Ploussard G; Rozet F; Roubaud G; Stanbury T; Sargos P; Roupret M
World J Urol; 2023 Feb; 41(2):361-369. PubMed ID: 36527470
[TBL] [Abstract] [Full Text] [Related]
3. HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial.
Couderc AL; Villani P; Berbis J; Nouguerède E; Rey D; Rossi D; Lechevallier É; Badinand D; Bastide C; Karsenty G; Boissier R; Amichi K; Muracciole X
BMC Cancer; 2022 Jan; 22(1):78. PubMed ID: 35042460
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract] [Full Text] [Related]
5. HoSAGE: Sarcopenia in Older Patients before and after treatment with Androgen Deprivation Therapy and Radiotherapy for prostate cancer.
Couderc AL; Muracciole X; Nouguerede E; Rey D; Schneider S; Champsaur P; Lechevallier E; Lalys L; Villani P
J Nutr Health Aging; 2020; 24(2):205-209. PubMed ID: 32003412
[TBL] [Abstract] [Full Text] [Related]
6. Response Prediction of
Rathke H; Holland-Letz T; Mier W; Flechsig P; Mavriopoulou E; Röhrich M; Kopka K; Hohenfellner M; Giesel FL; Haberkorn U; Kratochwil C
J Nucl Med; 2020 May; 61(5):689-695. PubMed ID: 31653712
[TBL] [Abstract] [Full Text] [Related]
7. Non-functional paraganglioma of urinary bladder managed by transurethral resection.
Zhang B; Fu Z; Liu L; Qiao B; Liu C
Int Braz J Urol; 2019; 45(5):910-915. PubMed ID: 31038858
[TBL] [Abstract] [Full Text] [Related]
8. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant prostate cancer: A Meta-Analysis.
Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
[TBL] [Abstract] [Full Text] [Related]
9. Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.
Conteduca V; Scarpi E; Salvi S; Casadio V; Lolli C; Gurioli G; Schepisi G; Wetterskog D; Farolfi A; Menna C; De Lisi D; Burgio SL; Beltran H; Attard G; De Giorgi U
Sci Rep; 2018 Oct; 8(1):15442. PubMed ID: 30337589
[TBL] [Abstract] [Full Text] [Related]
10. Cell-Free DNA and Neuromediators in Detecting Aggressive Variant prostate cancer.
von Hardenberg J; Worst TS; Westhoff N; Erben P; Fuxius S; Müller M; Bolenz C; Weiss C; Heinrich E
Oncol Res Treat; 2018; 41(10):627-633. PubMed ID: 30286478
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer.
Handforth C; Burkinshaw R; Freeman J; Brown JE; Snowden JA; Coleman RE; Greenfield DM
Support Care Cancer; 2019 May; 27(5):1755-1763. PubMed ID: 30143894
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.
Goineau A; Campion L; d'Aillières B; Vié B; Ghesquière A; Béra G; Jaffres D; de Laroche G; Magné N; Artignan X; Chamois J; Bergerot P; Martin E; Créhange G; Deniaud-Alexandre E; Buthaud X; Belkacémi Y; Doré M; de Decker L; Supiot S
PLoS One; 2018; 13(4):e0194173. PubMed ID: 29630602
[TBL] [Abstract] [Full Text] [Related]
13. Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study.
Honecker F; Wedding U; Kallischnigg G; Schroeder A; Klier J; Frangenheim T; Weißbach L
J Cancer Res Clin Oncol; 2018 Mar; 144(3):571-577. PubMed ID: 29299751
[TBL] [Abstract] [Full Text] [Related]
14. Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant prostate cancer Patients During Docetaxel.
VON Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Frangenheim T; Bolenz C; Weiss C; Heinrich E
Anticancer Res; 2017 Sep; 37(9):5117-5124. PubMed ID: 28870943
[TBL] [Abstract] [Full Text] [Related]
15. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive Geriatric Assessment in Men Aged 70 Years or Older with Localised prostate cancer Undergoing Radical Radiotherapy.
Osborne GEC; Appleyard SA; Gilbert DC; Jones CI; Lorimer C; Villanueva M; Peasgood E; Robinson A; Nikapota A; Ring A
Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):609-616. PubMed ID: 28592379
[TBL] [Abstract] [Full Text] [Related]
17. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
[TBL] [Abstract] [Full Text] [Related]
18. Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results.
Della Pepa C; Cavaliere C; Rossetti S; Di Napoli M; Cecere SC; Crispo A; De Sangro C; Rossi E; Turitto D; Germano D; Iovane G; Berretta M; D'Aniello C; Pisconti S; Maiorino L; Daniele B; Gridelli C; Pignata S; Facchini G
Anticancer Drugs; 2017 Jan; 28(1):104-109. PubMed ID: 27579728
[TBL] [Abstract] [Full Text] [Related]
19. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract] [Full Text] [Related]
20. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
[TBL] [Abstract] [Full Text] [Related]
[Next]
